Vaccinating against covid-19 in people who report allergies

BMJ. 2021 Jan 18:372:n120. doi: 10.1136/bmj.n120.

Authors

Rebecca E Glover¹, Robert Urquhart², Joanna Lukawska³, Kimberly G Blumenthal⁴

Affiliations

¹ AMR Centre, London School of Hygiene and Tropical Medicine, London, UK rebecca.glover@lshtm.ac.uk.
² University College London Hospitals NHS Trust, London, UK.
³ Department of Specialist Allergy and Clinical Immunology, University College London Hospitals, London, UK.
⁴ Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

PMID: 33461962
DOI: 10.1136/bmj.n120

No abstract available

Publication types

Editorial

MeSH terms

Anaphylaxis / chemically induced
Anaphylaxis / epidemiology*
BNT162 Vaccine
COVID-19 / prevention & control*
COVID-19 Vaccines / therapeutic use*
ChAdOx1 nCoV-19
Contraindications, Drug*
Drug Hypersensitivity / epidemiology
Drug Hypersensitivity / etiology
Humans
Patient Education as Topic
Patient Selection
Polyethylene Glycols / adverse effects
SARS-CoV-2
United Kingdom

Substances

COVID-19 Vaccines
Polyethylene Glycols
ChAdOx1 nCoV-19
polyethylene glycol 2000
BNT162 Vaccine